Transaction · 0001140361-26-019376

Eastling Thomas Wilson

Eastling Thomas Wilson, CFO, reported a transaction classified as grant at GYRE THERAPEUTICS, INC. involving 95060.000000 shares for an estimated $0.00. Reported holdings after the transaction were 95060.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACFO
GYREGYRE THERAPEUTICS, INC.
Trade date
May 04, 2026
Filing date
May 07, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded95.0k$0.00 per share
Holdings after95.0kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

GYRE price since this filing

Daily closing prices, with the filing date and available return windows
GYRE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -7.3%1w ago -7.3%1d ago +0.0%
Returns since7d +0.0%30d -25.5%90d -20.1%180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001140361-26-019376
Stock Option (Right to Buy)
Transaction date
May 04, 2026
Filed May 07, 2026, 12:38 AM · 3d delay
Shares
95,060 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
95,060 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-10 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This option is fully vested.

  2. F2

    This option represents a right to purchase 92,683 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly inst…

Original filing · 0001140361-26-019376
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

GYRE